Funding

  • PHS/FDA R01 FD005113: A Phase I study of a dual PI3K/BRD4 inhibitor, SF1126 in the treatment of hepatocellular carcinoma
  • Merck & Co, Inc.: Immunostimulatory activity of PD-1 blockade in tumor immunotherapy; effect on M1-M2 transition in macrophages
  • NIH R41 CA206859-01A1: Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
  • Olivia Hudson Foundation Donations
  • FDA R01 5R01FD004385-02: Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas
  • Cricket Communications: New Target for the Treatment of Cancer Metastasis
  • Hyundai Hope on Wheels 46944CA: Cancer Stem Cell Based Therapy with PI-3 kinase inhibitors for Medulloblastoma
  • Alex's Lemonade Stand Foundation Springboard Grant R01 FD00-04385-01-A1: Phase II Trial of Poly-ICLC in Pediatric Low Grade Gliomas
  • NIH R21CA173330-A1: Nanoparticle enabled L-asparaginase therapy for CLL
  • NIH R01 CA94233-10: Vascular targeted PI-3 kinase inhibitor for glioma therapy